SynthesisEuropean journal of human genetics : EJHG2009
The FAS ligand promoter polymorphism, rs763110 (-844C>T), contributes to cancer susceptibility: evidence from 19 case-control studies.
Synthesis in European journal of human genetics : EJHG, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 4 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- Association between CD95L polymorphism and cervical cancer risk: evidence from a meta-analysis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Pooled it
- Associations between Fas/FasL polymorphisms and susceptibility to cervical cancer: a meta-analysis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Pooled it
- CD95 rs1800682 polymorphism and cervical cancer risk: evidence from a meta-analysis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Pooled it
- FASL rs763110 polymorphism contributes to cancer risk: an updated meta-analysis involving 43,295 subjects.PloS one · 2013Pooled it
- Article
- Polygenic Risk Score Is Associated with Developing and Dying from Lung Cancer in the National Lung Screening Trial.Journal of clinical medicine · 2025Article
- Status of FAS and FAS Ligand Gene Polymorphisms in Patients with Breast Cancer in Northeastern IRAN.Reports of biochemistry & molecular biology · 2018Article
- Susceptibility to oral cancers with CD95 and CD95L promoter SNPs may vary with the site and gender.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
- Analysis of functional polymorphisms in apoptosis-related genes in primary open angle glaucoma.Molecular vision · 2015Article
- FasL gene -844T/C mutation of esophageal cancer in South China and its clinical significance.Scientific reports · 2014Article
- Death receptor (DR4) haplotypes are associated with increased susceptibility of gallbladder carcinoma in north Indian population.PloS one · 2014Article
- Caspase8 rs1035142 G>T polymorphism was associated with an increased risk of esophageal cancer in a Chinese population.Molecular biology reports · 2014Article
- Bladder cancer epidemiology and genetic susceptibility.Journal of biomedical research · 2013Article
- Functional polymorphisms in FAS/FASL system increase the risk of neuroblastoma in Chinese population.PloS one · 2013Article
- Functional polymorphisms of FAS and FASL gene and risk of breast cancer - pilot study of 134 cases.PloS one · 2013Article
- Polymorphisms of the FAS and FASL genes and risk of breast cancer.Oncology letters · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The potentially functional polymorphism, rs763110 (-844C>T), in the promoter region of the FAS ligand (FASL) gene, has been implicated in cancer risk, but individually published studies show inconclusive results. To derive a more precise estimation of the association between the FASL rs763110 and risk of cancer, we performed a meta-analysis of 19 published studies that included 11,105 cancer cases and 11,372 controls. We used odds ratios (ORs) and 95% confidence intervals (CIs) to assess the strength of the associations. Overall, the rs763110 CT and TT variant genotypes were associated with a significantly reduced cancer risk of all cancer types in different genetic models (homozygote comparison: OR=0.80, 95% CI: 0.68-0.95, P(heterogeneity)=0.001; heterozygote comparison: OR=0.82, 95% CI: 0.72-0.95, P(heterogeneity)<0.001; dominant model comparison: OR=0.82, 95% CI: 0.71-0.94, P(heterogeneity)<0.001; and recessive model comparison: OR=0.88, 95% CI: 0.81-0.96, P(heterogeneity)=0.074). In the stratified analyses, the risk remained for studies of the smoking-related cancers and Asian populations, or population-based studies in all the genetic models. Although some modest bias could not be eliminated, this meta-analysis suggests that the FASL rs763110 T allele has a possible protective effect on cancer risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.